Skip to content

Study · Animal study (in vivo) · rat · 1986

1 result

Central nervous system control of pituitary vasopressin receptors: evidence for involvement of multiple factors.

Lutz-Bucher B, Kovacs K, Makara G, Stark E, Koch B

Neuroendocrinology1 Jan 1986Cited by 7 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In Brattleboro rats, chronic oxytocin reduced pituitary vasopressin receptor concentration by 20-30%, compared with about 80% for the same dose of vasopressin.

    In plain wordsIn Brattleboro rats, long-term oxytocin lowered pituitary vasopressin receptors much less than the same dose of vasopressin did.

    Peptide
    Oxytocin
    Outcome
    DecreasePituitary AVP receptor concentration after chronic oxytocin
    Study

    ratn: not reported in source

    Brattleboro homozygous rats (lack AVP)
    Comparator
    Vasopressin (same dose)
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · chronicAs given in this study (rat).

    Measurements

    Receptor concentration reduction
    20 to 30%
    Brattleboro homozygous rats, oxytocin

    Source sentences

    Summary
    In HO, chronic administration of VP reduced receptor concentration by about 80%, while the same dose of oxytocin (OT) produced only a 20-30% reduction.
    1 context sentence
    Summary · context
    The regulation of pituitary vasopressin (VP) receptor concentration was investigated in rats with antero-lateral cuts (ALC) placed around the hypothalamus, as well as in Brattleboro homozygotes (HO) that genetically suffer from a lack of AVP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:54 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.